Trial of Acebilustat for the Treatment of Upper Arm Lymphedema
Status:
Not yet recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the response of unilateral upper extremity (arm)
lymphedema, during pharmacologic treatment of lymphedema with oral placebo and oral
acebilustat. Participants will receive "study drug" (Acebilustat or placebo), for 9 months.
For 3 of these months, the participant will receive placebo; for 6 of these months, the
participant will receive active ingredient, acebilustat. The study is blinded which means
that the participant will not be told which study pill they are taking.